Abstract
Human T cell leukemia virus type 1 (HTLV-1) transforms cytokine-dependent T lymphocytes and causes adult T cell leukemia. Janus tyrosine kinase (Jak)3 and transcription factors Stat5a and Stat5b are essential for the proliferation of normal T cells and are constitutively hyperactivated in both HTLV-1-transformed human T cell lines and lymphocytes isolated from HTLV-1-infected patients; therefore, a critical role for the Jak3-Stat5 pathway in the progression of this disease has been postulated. We recently reported that tyrphostin AG-490 selectively blocked IL-2 activation of Jak3/Stat5 and growth of murine T cell lines. Here we demonstrate that disruption of Jak3/Stat5a/b signaling with AG-490 (50 microM) blocked the proliferation of primary human T lymphocytes, but paradoxically failed to inhibit the proliferation of HTLV-1-transformed human T cell lines, HuT-102 and MT-2. Structural homologues of AG-490 also inhibited the proliferation of primary human T cells, but not HTLV-1-infected cells. Disruption of constitutive Jak3/Stat5 activation by AG-490 was demonstrated by inhibition of 1) tyrosine phosphorylation of Jak3, Stat5a (Tyr(694)), and Stat5b (Tyr(699)); 2) serine phosphorylation of Stat5a (Ser(726)) as determined by a novel phosphospecific Ab; and 3) Stat5a/b DNA binding to the Stat5-responsive beta-casein promoter. In contrast, AG-490 had no effect on DNA binding by p50/p65 components of NF-kappaB, a transcription factor activated by the HTLV-1-encoded phosphoprotein, Tax. Collectively, these data suggest that the Jak3-Stat5 pathway in HTLV-1-transformed T cells has become functionally redundant for proliferation. Reversal of this functional uncoupling may be required before Jak3/Stat5 inhibitors will be useful in the treatment of this malignancy.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Cell Line, Transformed
-
Cell Transformation, Neoplastic / drug effects
-
Cell Transformation, Neoplastic / immunology*
-
Cell Transformation, Neoplastic / pathology*
-
Cell Transformation, Viral / immunology*
-
DNA-Binding Proteins / antagonists & inhibitors
-
DNA-Binding Proteins / isolation & purification
-
DNA-Binding Proteins / metabolism
-
DNA-Binding Proteins / physiology*
-
Enzyme Inhibitors / pharmacology
-
Growth Inhibitors / pharmacology
-
Human T-lymphotropic virus 1 / immunology*
-
Humans
-
Immunosuppressive Agents / pharmacology
-
Interleukin-15 / antagonists & inhibitors
-
Interleukin-15 / pharmacology
-
Interleukin-2 / antagonists & inhibitors
-
Interleukin-2 / pharmacology
-
Janus Kinase 3
-
Lymphocyte Activation / drug effects
-
Milk Proteins*
-
NF-kappa B / metabolism
-
Nuclear Proteins / antagonists & inhibitors
-
Nuclear Proteins / metabolism
-
Phosphorylation / drug effects
-
Phytohemagglutinins / antagonists & inhibitors
-
Phytohemagglutinins / pharmacology
-
Protein-Tyrosine Kinases / antagonists & inhibitors
-
Protein-Tyrosine Kinases / isolation & purification
-
Protein-Tyrosine Kinases / metabolism
-
Protein-Tyrosine Kinases / physiology*
-
STAT5 Transcription Factor
-
Serine / antagonists & inhibitors
-
Serine / metabolism
-
Signal Transduction / drug effects
-
Signal Transduction / immunology*
-
T-Lymphocytes / drug effects
-
T-Lymphocytes / enzymology
-
T-Lymphocytes / immunology
-
T-Lymphocytes / pathology*
-
Trans-Activators / antagonists & inhibitors
-
Trans-Activators / isolation & purification
-
Trans-Activators / metabolism
-
Trans-Activators / physiology*
-
Tumor Cells, Cultured
-
Tumor Suppressor Proteins
-
Tyrosine / antagonists & inhibitors
-
Tyrosine / metabolism
-
Tyrphostins / pharmacology
Substances
-
DNA-Binding Proteins
-
Enzyme Inhibitors
-
Growth Inhibitors
-
Immunosuppressive Agents
-
Interleukin-15
-
Interleukin-2
-
Milk Proteins
-
NF-kappa B
-
Nuclear Proteins
-
Phytohemagglutinins
-
STAT5 Transcription Factor
-
STAT5A protein, human
-
STAT5B protein, human
-
Trans-Activators
-
Tumor Suppressor Proteins
-
Tyrphostins
-
alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide
-
Tyrosine
-
Serine
-
Protein-Tyrosine Kinases
-
JAK3 protein, human
-
Janus Kinase 3